Anti-SARS-CoV-2 antibody responses in convalescent plasma donors with varying clinical manifestation severity of COVID-19

Jasmina Grujić; Nevenka Bujandrić; Zorana Budakov Obradović; Nebojša Savić; Vladimir Dolinaj

doi:10.2298/VSP210301094G

Jasmina Grujić Blood Transfusion Institute of Vojvodina, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Department of Internal Medicine, Novi Sad, Serbia
Nevenka Bujandrić Blood Transfusion Institute of Vojvodina, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Department of Internal Medicine, Novi Sad, Serbia
Zorana Budakov Obradović Blood Transfusion Institute of Vojvodina, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Department of Internal Medicine, Novi Sad, Serbia
Nebojša Savić University Clinical Center of Serbia, Clinic for Vascular and Endovascular Surgery, Department of Transfusion Medicine, Belgrade, Serbia
Vladimir Dolinaj University Clinical Center of Vojvodina, Department of Anesthesiology, Novi Sad, Serbia

DOI: https://doi.org/10.2298/VSP210301094G

Keywords: antibody formation;, blood donors;, COVID-19 serotherapy;, immunization, passive;, plasma.

Abstract

Background/Aim. Plasma containing a high titer of anti-SARS-CoV-2 antibodies, donated from individuals who recovered from COVID-19, has the potential to be used as initial therapy for patients who have been infected (passive immunization). It is a challenge to find suitable donors. The aim of the study was to successively monitor antibody titer in donations and to investigate the correlation between antibody titer and the severity of the clinical manifestations. Methods. The retrospective study was conducted from May 1 to October 31, 2020, at the Blood Transfusion Institute of Vojvodina. Donors had to meet certain criteria for inclusion in the study: proven SARS-CoV-2 infection, detected SARS-CoV-2 antibodies in the serum/plasma, fulfillment of general criteria for performing plasmapheresis, and adequate laboratory findings. Results. During the study, 651 apheresis plasma units were collected and divided into two equal doses. Plasma was donated by 311 COVID-19 convalescents, including 208 (66.9%) men and 103 (33.1%) women. There were 15 (4.8%) plasma donors with asymptomatic infection, 235 (75. 6%) with a mild form of illness, 45 (14.5%) with a moderate form of illness, 16 (5.1%) with a severe form of illness, and none with a critical form of illness. Anti-SARS-CoV-2 IgG antibodies were present in the plasma of donors for more than 6 months after the disease. Plasma donors with a more severe clinical manifestation of COVID-19 had stable antibody levels for a longer period. However, the Pearson correlation of clinical severity and antibody titer did not confirm a statistically significant correlation between the variables. Conclusion. Anti-SARS-CoV-2 antibodies were present in the sample of recovered patients, plasma donors, for more than 6 months after the disease. Even though no statistically significant correlation was found between the anti-SARS-CoV-2 antibody titer and the clinical severity of COVID-19, in patients with a more severe clinical manifestations of the disease, stable antibody levels were maintained for a longer period.

References

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020; 382(13): 1199‒207.

2. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed 2020; 91(1): 157‒60.

3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–13.

4. WHO Coronavirus Disease (COVID-19) Dashboard. Available from: https://covid19.who.int/

5. Recommendations for investigational COVID-19 convalescent plasma-Food and Drug Administration; 2020. Available from: https://www.fda.gov/vaccines-blood-biologics/investigational
/>-new-drug-ind-or-device-exemption-ide-process-cber/recomm
endations-investigational-covid-19-convalescent-plasma.

6. World Health Organization. Guidance on maintaining a safe and adequate blood supply during the coronavirus disease 2019 (‎‎COVID-19)‎‎ pandemic and on the collection of COVID-19 convalescent plasma: interim guidance; 2020 Available from: https://apps.who.int/iris/handle/10665/333
/>182.

7. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130(4): 1545‒8.

8. Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al. The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis. Mayo Clin Proc 2021; 96(5): 1262‒75.

9. Liu A, Li Y, Wan Z, Wang W, Lei X, Lv Y. Seropositive prevalence of antibodies against SARS-CoV-2 in Wuhan, China. JAMA Netw Open 2020; 3(10): e2025717.

10. Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, et al. Covid-19-neutralizing antibodies predict disease severity and survival. Cell 2021; 184(2): 476‒88.e11.

11. Koutsakos M, Rowntree LC, Hensen L, Chua BY, Van de Sandt CE, Habel JR, et al. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Rep Med 2021; 2(3): 100208.

12. Ho MS, Chen WJ, Chen HY, Lin SF, Wang MC, Di J, et al. Neutralizing antibody response and SARS severity. Emerg Infect Dis 2005; 11(11): 1730‒7.

13. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis 2020; 26(7): 1478‒88.

14. Klein SL, Pekosz A, Park HS, Ursin RL, Shapiro JR, Benner SE, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest 2020; 130(11): 6141‒50.

15. Mendoza RP, Fyke W, Daniel D, Gabutan E, Das B, Bajaj H, et al. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes. Hum Immunol 2021; 82(4): 255‒63.

16. Pavlova IP, Nair SS, Kyprianou N, Tewari AK. The Rapid Coronavirus Antibody Test: Can We Improve Accuracy? Front Med (Lausanne) 2020; 7: 569.

17. Fridley GE, Le H, Yager P. Highly sensitive immunoassay based on controlled rehydration of patterned reagents in a 2-dimensional paper network. Anal Chem 2014; 86(13): 6447‒53.

18. Fu E, Liang T, Spicar-Mihalic P, Houghtaling J, Ramachandran S, Yager P. Two-dimensional paper network format that enables simple multistep assays for use in low-resource settings in the context of malaria antigen detection. Anal Chem 2012; 84(10): 4574‒9.

19. Gutierrez-Cobos A, Frutos SG, Garcia DD, Lara EN, Carrion AY, Garcia-Rodrigo LF, et al. Evaluation of diagnostic accuracy of 10 serologial assays for detection of SARS-CoV-2 antibodies. Eur J Clin Microbiol Infect Dis. 2020;24:1-7.

20. Szabó Z, Szabó T, Bodó K, Kemenesi G, Földes F, Kristóf K, et al. Comparison of virus neutralization activity and results of 10 different anti-SARS-CoV-2 serological tests in COVID-19 recovered plasma donors. Pract Lab Med 2021; 25: e00222.

21. Dulipsingh L, Ibrahim D, Schaefer EJ, Crowell R, Diffenderfer MR, Williams K, et al. SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma. Transfus Apher Sci 2020; 59(6): 102922.

22. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med 2020; 383(18):1724–34.

23. Lumley SF, O'Donnell D, Stoesser E, Matthews PC, Howarth A, Hatch SB, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med 2020; 384(6): 533–40.

24. Priyanka, Choudhary OP, Singh I. Protective immunity against COVID-19: Unravelling the evidences for humoral vs. cellular components. Travel Med Infect Dis 2021; 39: 101911.

25. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020; 38(1): 1‒9.

26. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26(8): 1200‒4.

27. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol 2020; 5(52):eabe0367.

28. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371(6529): eabf4063.

29. Balint B, Todorović Balint M, Anrić Z, Jovičić M, Blagojević G, Čolić M. Long-term antibody-response monitoring following primary exposure to SARS-COV-2 and afterward mRNA COVID-19 vaccination: A case report. Vojnosanitet Pregl 2021; 78(3): 379‒81.

30. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS‐CoV‐2 spike antigens in COVID‐19 patients. Sci Immunol 2020; 5(52): eabe5511.

31. Thieme CJ, Anft M, Paniskaki K, Blazquez-Navarro A, Doevelaar A, Seibert FS, et al. Robust T cell response toward spike, membrane, and nucleocapsid SARS‐CoV‐2 proteins is not associated with recovery in critical COVID‐19 patients. Cell Reports Med 2020; 1(6): 100092.

32. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hpffman C, Hausner MA, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med 2020; 383(11): 1085–87.

33. Kong WH, Zhao R, Zhou JB, Wang F, Kong DG, Sun JB, et al. Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity. Virol Sin 2020; 35(6): 752‒7.

34. Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y, et al. Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19. Front Mol Biosci 2020; 7: 157.

35. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis 2020; 71(16): 2027‒34.

36. Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol 2020; 5(54): eabe0240.

37. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020; 26(6): 845‒8.

38. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130(5): 2620‒9.